

12 October 2026

Argent BioPharma Advances Focused Immune Modulation and Inflammatory Disease Strategy

Highlights:

- **Argent BioPharma consolidates its strategy around immune modulation and inflammatory disease following the global licensing of CannEpil®**
- **RGT-CA91980 established as the Company's lead internally developed pharmaceutical programme, building on the clinical and preclinical development history of Cimetra® and ArtemiC**
- **Licensed commercialisation rights to the NLC portfolio add complementary antiviral and immune-modulating products.**
- **NanoBodies expands the Company's pipeline into next-generation vascular and peptide-mediated immune modulation**
- **Company evaluating a disciplined research programme examining chronic inflammation, inflammaging and healthy ageing biology**

Argent BioPharma Limited (ASX: RGT) ("**Argent BioPharma**", "**Argent**" or the "**Company**") is pleased to provide shareholders with an update on the Company's strategic direction following the global licensing of CannEpil®, expansion of its pharmaceutical development programmes and continued advancement of its immune modulation portfolio.

Argent is building a focused immune science company centred on understanding and managing inflammatory escalation across acute, chronic and age-associated biological settings, extending its immune-modulation expertise into the emerging fields of healthy ageing and longevity research.

The Company's portfolio brings together internally led pharmaceutical development, advanced drug delivery, early-stage biologic research and selectively licensed commercial products. Each asset will be developed through the regulatory and commercial pathway appropriate to its scientific evidence, ownership structure and intended use.

This strategy is designed to concentrate the Company's scientific and financial resources around a coherent area of expertise while maintaining multiple routes to value through pharmaceutical development, intellectual property, commercialisation, manufacturing, licensing and strategic partnerships.

CannEpil® Establishes the Partner-Led Development Model

The global licensing of CannEpil® represented an important transition in Argent BioPharma's operating model.

CannEpil® was advanced by Argent from pharmaceutical development through regulated market-access programmes before transitioning into a global commercial licensing partnership.

The transaction resulted in the extinguishment of approximately US\$5 million of secured convertible debt, materially strengthening the Company's balance sheet while preserving Argent's long-term economic participation in the asset.

Argent retains ownership of the existing and future CannEpil® intellectual property covered by the licensing arrangement and maintains an ongoing role within the product's manufacturing and supply framework. The licensing partner is responsible for development and commercialisation within the licensed scope.

The subsequent expansion of CannEpil® into veterinary medicine and progress through the U.S. FDA Center for Veterinary Medicine demonstrate how Argent intends to use strategic partnerships to advance established assets while directing its internal resources toward its core pharmaceutical development programmes.

This structure provides a model through which Argent can retain long-term economic exposure to partnered assets while concentrating internal capital and scientific resources on immune modulation and inflammatory disease.

Core Research Focus

Argent's internally led pharmaceutical strategy is increasingly focused on immune modulation and inflammatory disease, with emerging research into inflammaging, healthy ageing and longevity as a natural extension of the Company's immune science platform.

CimetrA®: Expanding Immune Modulation into Healthy Ageing and Longevity Research


Chronic low-grade inflammation is increasingly recognised as an important biological feature of ageing, commonly described as inflammaging. This creates a natural extension of Argent BioPharma's immune-modulation strategy into the biology of healthy ageing and longevity.

CimetrA® provides an established scientific and clinical foundation from which the Company intends to develop this research direction. The programme has generated laboratory, preclinical and human clinical data across inflammatory and cellular stress pathways relevant to chronic inflammation, including cytokine regulation, oxidative stress, inflammasome-associated biology and cellular resilience.

Laboratory research has demonstrated measurable changes across multiple inflammatory biomarkers, including IL-32, CXCL10, IFN γ , TNF α , IL-6, IL-18, MCP-1 and IL-1 β , together with increased HO-1 expression. These observations, combined with the existing human safety and clinical experience accumulated through the CimetrA® development programme, provide the Company with a substantive foundation for progressing dedicated research into inflammaging and healthy ageing biology.

Argent therefore intends to expand the CimetrA® research programme into **healthy ageing and longevity science**, with a focus on understanding whether modulation of chronic inflammatory and cellular stress pathways can influence biomarkers associated with biological ageing, immune resilience and age-related functional decline.

The next stage is expected to evaluate defined inflammatory, oxidative stress, metabolic and biological-age biomarkers through a dedicated research framework, building upon the Company's existing clinical and translational data rather than commencing a new discovery programme from first principles.



This programme forms part of Argent BioPharma's broader strategy to apply its immune-modulation science across the continuum of **acute inflammation, chronic inflammatory disease and age-associated inflammation**, establishing longevity research as an additional development vertical within the Company's focused immune science platform.

Selective Expansion Through NLC Commercialisation Rights

Argent has secured licensed commercialisation rights to the NLC portfolio, including Tollovir™, Tollovid™ and NutraVir™.

The NLC portfolio is based on mechanism-driven approaches to antiviral activity and immune modulation and provides a complementary commercial platform alongside Argent's internally led pharmaceutical development programmes.

Importantly, **NLC retains ownership of the underlying NLC intellectual property and improvements**. Argent's rights relate to commercialisation within the scope of the applicable licence and should not be interpreted as an acquisition of NLC, ownership of its underlying technology or rights outside the agreed licensed field.

The Company believes the NLC commercialisation rights provide an opportunity to participate in complementary antiviral and immune-modulating markets without requiring Argent to redirect its core pharmaceutical development resources.

This structure is consistent with the Company's broader capital-efficient strategy of combining internally owned pharmaceutical development with selectively licensed commercial opportunities.

NanoBodies: Next-Generation Immune Modulation

Argent's NanoBodies programme represents the next-generation biologic component of the Company's immune modulation strategy.

The early-stage platform is focused on vascular and peptide-mediated signalling mechanisms implicated in septic shock and systemic inflammatory disorders.


The Company has filed United States provisional patent application **No. 63/979,136** covering designated peptide targets and associated nanobody constructs.

Planned proof-of-concept work is intended to evaluate vascular stability, inflammatory biomarkers and immune responses in a recognised translational model of septic shock.

The NanoBodies programme remains preclinical, and the provisional patent application does not represent a granted patent.

The programme provides longer-term scientific optionality and expands Argent's research beyond its existing pharmaceutical formulations into precision peptide and nanobody-based immune modulation.





Strategic Priorities

Over the next phase of development, Argent BioPharma intends to focus on four core priorities:

Commercialisation and Revenue Generation

Accelerate the commercialisation of CimetrA® and the licensed NLC portfolio, expanding market access and product revenues. The Company's immediate commercial priority is to generate revenue from assets that are already capable of reaching the market, creating a stronger financial foundation from which to fund future pharmaceutical and research programmes.

CannEpil® Licensing, Manufacturing and Regulatory Support

Support the continued development and commercialisation of CannEpil® under the Company's global licensing model, including manufacturing and supply activities and support for ongoing FDA development programmes. This strategy enables Argent to generate and expand manufacturing and royalty revenues while its licensing partner funds and leads the broader development and commercialisation pathway.

Expand Inflammaging and Longevity Research

Build upon the Company's existing clinical, preclinical and translational evidence to develop a dedicated research programme focused on inflammaging, immune resilience, healthy ageing and longevity. The programme will examine validated inflammatory, cellular stress and biological-age biomarkers and extend Argent's immune-modulation expertise into the emerging field of longevity science.

The Company will continue development of RGT-CA91980 and the NanoBodies programme within this broader scientific platform, with development expenditure prioritised against evidence, commercial opportunity and available resources.


Corporate and Capital Markets Positioning

Position Argent BioPharma as a revenue-generating immune science company combining commercial products, pharmaceutical development, proprietary and licensed intellectual property, manufacturing, royalties and longevity research.

The Company intends to use this increasingly focused operating model to strengthen its corporate profile, broaden access to international capital and strategic partners, and support the next stage of its U.S. capital markets strategy.

Argent BioPharma's approach is deliberately commercially led and capital disciplined, with near-term revenue generation and existing commercial assets intended to support the progressive development of its pharmaceutical and research portfolio.





Roby Zomer, Executive Chairman, commented:

"The CannEpil® licence marked an important inflection point for Argent BioPharma. It demonstrated our ability to create value from an established asset, place that asset with a dedicated development and commercial partner, retain long-term economic participation and redirect our internal resources toward immune modulation and inflammatory disease.

Our strategy is now much clearer. RGT-CA91980 provides an established human clinical foundation for further inflammatory disease development, while NanoBodies expands our research into upstream vascular and peptide-mediated signalling. Our drug delivery capabilities and selectively licensed commercial platforms provide additional routes through which our science and existing infrastructure can create value.

We also see an emerging research opportunity at the intersection of chronic inflammation and healthy ageing. We are not presenting CimetrA® as an anti-ageing medicine. Our objective is to develop and test a disciplined scientific hypothesis around inflammaging using appropriate biomarkers and controlled research.

Together, these programmes provide Argent with a more focused scientific identity and a clearer capital allocation strategy as we build the next phase of the Company."

—Ends—

Authorised for release by the board of directors, for further information please contact:

Argent BioPharma

Roby Zomer

Chairman

+61 8 6555 2950

info@argentbiopharma.com

Argent BioPharma

Rowan Harland

Company Secretary

+61 8 6555 2950

info@argentbiopharma.com

About Argent BioPharma

Argent BioPharma Limited (ASX: RGT) is a revenue-generating immune science and specialty biopharmaceutical company focused on the development and commercialisation of technologies across immune modulation, inflammatory disease and precision drug delivery.

The Company's portfolio combines internally developed pharmaceutical programmes, owned intellectual property, licensed commercialisation rights, early-stage biologic technologies, commercial products, manufacturing capabilities and strategic licensing partnerships.

Argent BioPharma's strategy is to concentrate internal development resources on differentiated immune modulation technologies while using commercialisation, manufacturing and strategic partnerships to create additional routes to long-term value.

